Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments

Chiara Piubelli; Matteo Valerio; Matteo Verzè; Fabrizio Nicolis; Carlotta Mantoan; Sonia Zamboni; Francesca Perandin; Eleonora Rizzi; Stefano Tais; Monica Degani; Sara Caldrer; Federico Giovanni Gobbi; Zeno Bisoffi; Stefania Gori

doi:10.3389/fonc.2023.1089944

Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments

Front Oncol. 2023 Feb 22:13:1089944. doi: 10.3389/fonc.2023.1089944. eCollection 2023.

Affiliations

¹ Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Vr, Italy.
² Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Vr, Italy.
³ Medical Direction Unit, Medical Direction, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Vr, Italy.
⁴ Nurse Direction Unit, Nurse Direction, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Vr, Italy.

Abstract

Introduction: Cancer patients are at risk for serious complications in case of SARS-CoV-2 infection. In these patients SARS-CoV-2 vaccination is strongly recommended, with the preferential use of mRNA vaccines. The antibody response in cancer patients is variable, depending on the type of cancer and antitumoral treatment. In solid tumor patients an antibody response similar to healthy subjects has been confirmed after the second dose. Only few studies explored the duration of immunization after the two doses and the effect of the third dose.

Methods: In our study we explored a cohort of 273 solid tumor patients at different stages and treated with different anticancer therapies.

Results and discussion: Our analysis demonstrated that the persistence of the neutralizing antibody and the humoral response after the booster dose of vaccine was not dependent on either the tumor type, the stage or type of anticancer treatment.

Keywords: Comirnaty; IgG; SARS-CoV-2; anticancer treatment; metastasis; neutralizing antibodies; solid tumors.

Grants and funding

The work performed at the Department of Infectious, Tropical Diseases and Microbiology was supported by the Italian Ministry of Health under “Fondi Ricerca Corrente”- project L1P5.